CHMP recommends EU approval of Roche’s fixed-duration Columvi for large B-cell lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The partnership will capitalize on the combined capabilities of the two organizations
The appointment is effective from May 01, 2023 for five years
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Apollo continues to invest in genomics technology and research for better patient care
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Subscribe To Our Newsletter & Stay Updated